Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Reproductive Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RBMY1F drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RBMY1F Recombinant Protein (RRM Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. |
View RBMY1F Products |
| Gene Delivery | RBMY1F Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View RBMY1F Products |
| Benchmark Ab | Anti-RBMY1F Recombinant Antibody High-affinity positive control for IHC, WB, and IP validation. |
View RBMY1F Products |
| Validator | RBMY1F siRNA Set Target-specific knockdown verification to rule out off-target effects. |
View RBMY1F Products |
| Related Target A | RBMY1A1 Highly homologous family member; essential for off-target selectivity screening. |
View RBMY1A1 Products |
| Related Target B | HSPA2 Chaperone protein interacting with RBMY family during spermatogenesis and oncogenesis. |
View HSPA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology across RBMY family (off-target risk) | Sequence Verified recombinant proteins with strict batch-to-batch identity validation via LC-MS/MS. |
| RNA-binding activity validation requirements | High Purity (>95% by SDS-PAGE) and low endotoxin (<1.0 EU/μg) ensuring minimal interference in RNA electrophoretic mobility shift assays (EMSA). |
| Lack of reliable positive control antibodies | Recombinant Benchmark Antibodies available, guaranteeing consistent performance without lot-to-lot variation. |
| False positive phenotype confirmation | Sequence-specific siRNA sets included for functional knockdown rescue and validation. |
Live RBMY1F R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of RBMY1F (RNA Binding Motif Protein, Y-Linked, Family 1, Member F) is gaining momentum as researchers delve deeper into its dual role as a Cancer-Testis Antigen (CTA) in hepatocellular carcinoma (HCC) and its physiological function in spermatogenesis. While historically studied in the context of male infertility, its aberrant overexpression in male-biased cancers makes it an attractive, highly specific therapeutic target.
The next wave of R&D is focusing on exploiting RBMY1F's restricted physiological expression to develop highly targeted immunotherapies, including TCR-T cell therapies and cancer vaccines, alongside small-molecule inhibitors designed to disrupt its RNA-binding pocket.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / Immunotherapy | Academic Institutes, Biotech Startups | Hepatocellular Carcinoma (HCC) | HLA-peptide binding assays require precise target sequence validation. |
| Small Molecule Inhibitors | Oncology-focused Biopharma | Solid Tumors (Male-biased) | High-purity RRM domain proteins for FP/TR-FRET binding screens. |
| RNA Therapeutics | Gene Therapy Pioneers | Azoospermia, Male Infertility | Lentiviral-mediated overexpression models to evaluate functional rescue. |